You are here

Article Text

Article menu
Download PDFPDF
Unexpected outcome (positive or negative) including adverse drug reactions
Case report
Immune checkpoint inhibitor induced large vessel vasculitis
  1. Daisy Henderson1,
  2. Gelareh Eslamian2,
  3. Daniel Poon3,
  4. Simon Crabb4,
  5. Robert Jones5,
  6. Peter Sankey6,
  7. Bihani Kularatne7,
  8. Mark Linch8 and
  9. Debra Josephs2
  1. 1Department of Palliative Care, Royal Free London NHS Foundation Trust, London, UK
  2. 2Department of Medical Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK
  3. 3Department of Radiology, Guy's and St Thomas' NHS Foundation Trust, London, UK
  4. 4Cancer Sciences Unit, University of Southampton, Southampton General Hospital, Southampton, UK
  5. 5Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
  6. 6Department of Clinical Oncology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK
  7. 7Department of Medical Oncology, University College London Hospitals NHS Foundation Trust, London, UK
  8. 8Department of Oncology, University College London Cancer Institute, London, UK
  1. Correspondence to Dr Daisy Henderson; daisyhenderson{at}nhs.net

Abstract

This is a case report of a 67-year-old patient with castration resistant metastatic prostate cancer who developed an immune-mediated large vessel vasculitis following treatment with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1).

  • prostate cancer
  • vasculitis
  • unwanted effects / adverse reactions
  • immunology
  • cancer intervention

https://doi.org/10.1136/bcr-2019-233496

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Twitter @RadDSP

    • Contributors DH, GE, DP and DJ: conception and design of case report; acquisition, analysis and interpretation of data and drafting and revising the article. SC, RJ, PS, BK and ML: analysis and interpretation of data and drafting and revising the article. All authors gave final approval of the article and have agreed to be accountable for all aspects of the work.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient consent for publication Obtained.

    • Provenance and peer review Not commissioned; externally peer reviewed.